Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-08
2008-04-08
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S405000, C514S407000, C514S307000, C548S138000, C548S137000, C548S361100, C548S364100, C546S113000, C546S139000
Reexamination Certificate
active
07354944
ABSTRACT:
The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
REFERENCES:
patent: 3452035 (1969-06-01), Berkelhammer et al.
patent: 3666860 (1972-05-01), Berkelhammer et al.
patent: 3740434 (1973-06-01), Berkelhammer et al.
patent: 3830924 (1974-08-01), Berkelhammer et al.
patent: 3842174 (1974-10-01), Berkelhammer et al.
patent: 3904756 (1975-09-01), Berkelhammer et al.
patent: 3991200 (1976-11-01), Berkelhammer et al.
patent: 4086238 (1978-04-01), Krenzer
patent: 4146400 (1979-03-01), Lowski et al.
patent: 4596802 (1986-06-01), Wermuth et al.
patent: 5086053 (1992-02-01), Brodin et al.
patent: 5834401 (1998-11-01), Kawamura et al.
patent: 5977027 (1999-11-01), Kawamura et al.
patent: 6323315 (2001-11-01), Pettit et al.
patent: 6420400 (2002-07-01), Zhang et al.
patent: 6620911 (2003-09-01), Pettit et al.
patent: 6894054 (2005-05-01), Laborde et al.
patent: 2002/0115863 (2002-08-01), Patel et al.
patent: 2002/0119962 (2002-08-01), Jacobs et al.
patent: 2004/0102360 (2004-05-01), Barnett et al.
patent: 2004/0106540 (2004-06-01), Barnett et al.
patent: 2004/0122016 (2004-06-01), Cao et al.
patent: 2005/0043372 (2005-02-01), Chen et al.
patent: 2005/0053594 (2005-03-01), Alessi et al.
patent: 2005/0143384 (2005-06-01), Sartori et al.
patent: 2005/0222219 (2005-10-01), Chen et al.
patent: 2006/0003944 (2006-01-01), Glinka et al.
patent: 3407505 (1985-09-01), None
patent: WO 93/19054 (1993-09-01), None
patent: WO 96/38419 (1996-12-01), None
patent: WO 97/22360 (1997-06-01), None
patent: WO 99/31096 (1999-06-01), None
patent: WO 01/44178 (2001-06-01), None
patent: WO 01/44179 (2001-06-01), None
patent: WO 02/083064 (2003-10-01), None
patent: WO 03/084473 (2003-10-01), None
patent: WO 03/094831 (2003-11-01), None
patent: WO 2004/014864 (2004-02-01), None
patent: WO 2004/056789 (2004-07-01), None
patent: WO 2004/096131 (2004-11-01), None
patent: WO 2005/014554 (2005-02-01), None
patent: WO 2005/046678 (2005-05-01), None
patent: WO 2005/089443 (2005-09-01), None
patent: WO 2005/113762 (2005-12-01), None
patent: WO 2006/045716 (2006-05-01), None
STN search result (2 pages): Abstract of Fathalla et al. Egyptian Journal of Chemistry (2003), 46(1), pp. 135-152.
Bellacosa, et al., “Molecular Alterations of the AKT2 Oncogene in Ovarian and Breast Carcinomas”,Int. J. Cancer, 64, 280-285 (1995).
Besson, et al., “PTEN/MMAC/TEP1 in Signal Transduction and Tumorigenesis”,Eur. J. Biochem., 263, 605-611 (1999).
Blume-Jensen, et al., “Oncogenic Kinase Signalling”,Nature, 411, 355-365 (2001).
Brodbeck, et al., “A Human Protein Kinase By with Regulatory Phosphorylation Sites in the Activation Loop and in the C-terminal Hydophobic Domain”,J. Biol. Chem., 274, 9133-9136 (1999).
Cheng, et al., “AKT2, a Putative Oncogene Encoding a Member of a Subfamily of Protein-Serine/Threonine Kinases, is Amplified in Human Ovarian Carcinomas”,Proc. Natl. Acad. Sci. U.S.A., 89, 9267-9271 (1992).
Datta, et al. “Cellular Survival: A Play In Three AKTS”,Genes Dev., 13, 2905-2927 (1999).
Lawlor et al., “PKB/AKT: A Key Mediator of Cell Proliferation, Survival and Insulin Responses?”,J. Cell Sci., 114, 2903-2910 (2001).
Lin, et al., “AKT Suppresses Androgen-Induced Apoptosis by Phosphorylating and Inhibiting Androgen Receptor”,Proc. Natl. Acad. Sci. U. S. A., 98, 7200-7205 (2001).
Luo, et al., “Acute Modulation of Endothelial AKT/PKB Activity Alters Nitric Oxide-Dependent Vasomotor Acitivity In Vivo”,J. Clin. Invest., 106, 493-499 (2000).
Mazzone et al., “Synthesis and Local Anesthetic Activity of Alkylaminoacyl Derivatives of 2-Amino-1,3,4-Thiadiazole”,II Farmaco, 48(9), 1207-1224 (1993).
Cheng, et al., “Amplification of AKT2 in Human Pancreatic Cancer Cells and Inhibition of AKT2 Expression and Tumorigenicity by Antisense RNA”,Proc. Natl. Acad. Sci. U.S.A., 93, 3636-3641 (1996).
Czech, et al., “Signaling Mechanisms That Regulate Glucose Transport”,J. Biol. Chem., 274, 1865-1868 (1999).
Duan et al., “Phosphatidylinositol 3-Kinase Is Required for Insulin-Like Growth Factor-I-Induced Vascular Smooth Muscle Cell Proliferation and Migration”,Circ. Res., 86, 15-23 (2000).
Fennel, B. J. et al., “Effects of the Antimitotic Natural Product Dolastatin 10, and Related Peptides, on the Human Malarial Parasite Plasmodium Falciparum”,J. Antimicrobial Chemotherapy, 51(4), 833-841 (2003).
Hackbarth Corinne K., et al., “N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity”,Antimicrobial Agents and Chemotherapy, 46(9), 2752-2764 (2002).
Hemmings, Brian A., “AKT Signaling: Linking Membrane Events to Life and Death Decisions”,Science, 275, 628-630 (1997).
Hill et al., “Identification of a Plasma Membrane Raft-Associated PKB Ser473 Kinase Activity that is Distinct from ILK and PDK1”,Current Biology, 12, 1251-1255 (2002).
Hiremath, S.P. et al., “Synthesis of 2-Phenyl(indol-3-yl)isothiocyanates, 1-Substituted-3-(substituted-2′-phenylindol-3′yl)thiosemicarbazides and their Reactions”,Indian Journal of Heterocyclic Chemistry, 2(2), 119-124 (1992).
Hiremath, S.P. et al., “Synthesis of Substituted Indolylthiadiazolines and Indolylisoxazolines”,Indian J. Chem., 30B(8), 744-748 (1991).
Hresko et al., “Phosphoinositide-Dependent Kinase-2 Is a Distinct Protein Kinase Enriched In a Novel Cytoskeletal Fraction Associated with Adipocyte Plasma Membranes”,J. Biol. Chem., 278, 21615-21622 (2003).
Khwaja, “AKT Is More Than Just a Bad Kinase”,Nature, 401, 33-34 (1999).
Kidwai, Mazaahir et al., “Solid Supported Reaction of Substituted 2-Oxazoline with Amines Under Microwave Irradiation”,J. Chinese Chem. Soc., 50(5), 1075-1078 (2003).
Kidwai, Mazaahir, et al., “Microwave Induced Synthesis and Antibacterial Activity of Cephalosporin Derivatives Using Solid Support”,Bioorganic Chemistry, 29(6), 380-386 (2001).
Kulik et al., “Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and AKT”,Mol. Cell. Biol., 17, 1595-1606 (1997).
Kureishi, et al., “The HMG-CoA Reductase Inhibitor Simvastatin Acitivates the Protein Kinase AKT and Promotes Angiogenesis In Normocholesterolimic Animals”,Nat. Med., 6, 1004-1010 (2000).
Li, et al., “TEP1, Encoded by a Candidate Tumor Suppressor Locus, is a Novel Protein Tyrosine Phosphatase Regulated by Transforming Growth Facto β1”,Cancer Res.57, 2124-2129 (1997).
Miao et al., “Intracoronary, Adenovirus-Mediated AKT Gene Transfer In Heart Limits Infarct Size Following Ischemia-Reperfusion Injury In Vivo”,J. Mol. Cell. Cardiol., 32, 2397-2402 (2000).
Namikawa, et al., “AKT/Protein Kinase B Prevents Injury-Induced Motoneuron Death and Accelerates Axonal Regeneration”,J Neurosci., 20, 2875-2886 (2000).
Nicholson, et al., “The Protein Kinase B/AKT Signalling Pathway In Human Malignancy”,Cell. Signal., 14, 381-395 (2002).
Pachhamia et al., “Studies on Thiadiazoles: Part-1: Preparation and Antimicrobial Acitivity of 2-(α-Carbamylarylmethy-Lamino)-5-(4′-Pyridyl)-1, 3, 4-Thiadiazoles”,J. Inst. Chemists(India), 61, 54-56 (1989).
Pande, Kalpana, et al., “Anti-inflammatory and Antiproteolytic Activities of Substituted Imidazolones”,Indian Drugs, 23(1), 13-17 (1985).
Pettit, Robin K., et al., “Specific Activities of Dolastatin 10 and Peptide Derivatives AgainstCryptococcus neoformans”,Antimicrobial Agents and Chemotherapy, 42(11), 2961-2965 (1998).
Senapati, R.M., et al., “Studies on Thiadiazoles”,Pro
Bourbeau Matthew Paul
Dominguez Celia
Monenschein Holger
Rider James Thomas
Tasker Andrew
Amgen Inc.
Anderson Rebecca
Chu Yong
Friedrichsen Bernard P.
LandOfFree
Thiadiazole compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiadiazole compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiadiazole compounds and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2770515